C87977 Inhibitors
C87977 inhibitors are a class of chemical compounds designed to selectively target the Pramel29 protein, a member of the PRAME (Preferentially Expressed Antigen in Melanoma) family. This family of proteins is involved in regulating various cellular processes, particularly those associated with gene expression and immune modulation. C87977 inhibitors bind specifically to the Pramel29 protein, influencing its structure and activity. This interaction often results in the modulation of downstream cellular pathways controlled by Pramel29, which can have significant effects on various biological processes such as cellular proliferation and differentiation. These inhibitors are widely utilized in research settings to gain deeper insights into how Pramel29 functions at the molecular level.
The specificity of C87977 inhibitors to Pramel29 makes them invaluable tools for studying the complex interactions of this protein within the cellular environment. By interfering with Pramel29's activity, researchers can observe changes in the regulation of gene expression and other critical cellular functions. These inhibitors have proven useful in experiments aimed at understanding how Pramel29 contributes to normal cellular operations, as well as its involvement in specific signaling networks. The use of C87977 inhibitors helps in elucidating the molecular mechanisms that govern the role of Pramel29 in cellular dynamics, offering researchers a better understanding of how modulation of this protein affects broader biological systems.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits NEDD8-activating enzyme (NAE), blocking the activation of cullin-based ubiquitin ligases, including Cul2-RING. Disruption of this activation may impact the Cul2-RING complex, potentially influencing Pramel29 ubiquitination and degradation. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
Cyclin-dependent kinase (CDK) inhibitor affecting cell cycle progression. Inhibition of CDKs may indirectly influence Cul2-RING complex function and subsequently impact Pramel29 regulation through ubiquitination processes. | ||||||
MLN 8054 | 869363-13-3 | sc-484828 | 5 mg | $398.00 | ||
Inhibits Aurora A kinase, potentially influencing the Cul2-RING complex dynamics. Alterations in the complex may indirectly affect Pramel29 ubiquitination and turnover, highlighting the interconnected nature of the ubiquitin-proteasome system. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
BET bromodomain inhibitor affecting gene transcription. As Cul2-RING complexes can ubiquitinate certain transcription factors, JQ1 may indirectly influence Pramel29 through alterations in the ubiquitin-mediated regulation of transcription factors associated with Cul2-RING. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Exhibits anti-inflammatory properties and may modulate the Cul2-RING ubiquitin ligase complex indirectly. Changes in the complex could impact Pramel29 ubiquitination and stability, suggesting a potential link between inflammation signaling and Pramel29 regulation. | ||||||
CC-401 | 395104-30-0 | sc-364748 sc-364748A | 2 mg 10 mg | $331.00 $1060.00 | 4 | |
JAK2 inhibitor impacting the JAK-STAT signaling pathway. As Cul2-RING complexes can ubiquitinate proteins involved in the JAK-STAT pathway, inhibition of JAK2 may indirectly affect Pramel29 regulation through alterations in the ubiquitin-mediated turnover of pathway components. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Immunomodulatory drug impacting the E3 ubiquitin ligase complex. By affecting the ubiquitin-proteasome system, lenalidomide may indirectly influence Pramel29 ubiquitination and degradation, potentially connecting immune modulation with Pramel29 regulation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor disrupting protein degradation pathways. Inhibition of the proteasome may indirectly affect Pramel29 by preventing its ubiquitin-mediated degradation, providing insights into the potential role of the Cul2-RING ubiquitin ligase complex in Pramel29 regulation and stability. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
TGF-βRI kinase inhibitor impacting the TGF-β signaling pathway. As TGF-β signaling involves the Cul2-RING ubiquitin ligase complex, SD-208 may indirectly influence Pramel29 regulation through alterations in the ubiquitin-mediated turnover of proteins associated with the TGF-β pathway. | ||||||